Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
- Conditions
- HIV InfectionHIV-1 InfectionMycobacterium Avium Complex (MAC)
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01894776
- Locations
- 🇨🇦
The Ottawa Hospital -General Campus, Ottawa, Ontario, Canada
Switching Undetectables to Selzentry
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- St. Hope Foundation
- Target Recruit Count
- 31
- Registration Number
- NCT01866267
- Locations
- 🇺🇸
St. Hope Foundation, Inc., Bellaire, Texas, United States
Phase II Maraviroc for GVHD Prevention
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 37
- Registration Number
- NCT01785810
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Emory University
- Target Recruit Count
- 31
- Registration Number
- NCT01749566
- Locations
- 🇺🇸
Grady Infectious Diseases Program, Atlanta, Georgia, United States
CCR5-blockade in Metastatic Colorectal Cancer
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- National Center for Tumor Diseases, Heidelberg
- Target Recruit Count
- 12
- Registration Number
- NCT01736813
- Locations
- 🇩🇪
National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Baden-Württemberg, Germany
First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 10
- Registration Number
- NCT01719627
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 19
- Registration Number
- NCT01680536
- Locations
- 🇬🇧
St Stephen's AIDS Trust, London, United Kingdom
The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Target Recruit Count
- 11
- Registration Number
- NCT01627717
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT01597895
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
- Conditions
- Infection, Human Immunodeficiency Virus I
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT01597648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.